Patient-reported data on the severity of Von Willebrand disease
The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD. The study aimed to in...
Gespeichert in:
| Veröffentlicht in: | Haemophilia : the official journal of the World Federation of Hemophilia 2024-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Haemophilia : the official journal of the World Federation of Hemophilia |
| container_volume | |
| creator | van Kwawegen, Calvin B Fijnvandraat, Karin Kruip, Marieke J H A de Meris, Joke Schols, Saskia E M Meijer, Karina van der Bom, Johanna G Cnossen, Marjon H van Galen, Karin P M Atiq, Ferdows Eikenboom, Jeroen Leebeek, Frank W G |
| description | The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD.
The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients.
Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL).
We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels |
| doi_str_mv | 10.1111/hae.15103 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3116678511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3116678511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c210t-4f4c837c037b023ed3e6c16410cab261534f29a9fe3f81826c0693be1aa1cd613</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqWw4AdQlrBI8XgSJ1khVPGSKsGCx9JynLEalCbFdpD69yS0cDdzNTq6i8PYOfA5DLleaZpDChwP2BRQprFIQR6OPYU4FyAn7MT7T84BBZfHbIJFwjGXyZTdvOhQUxtiR5vOBaqiSgcddW0UVhR5-iZXh23U2eh9-H3UTUOl0-2A1Z60p1N2ZHXj6Wx_Z-zt_u518Rgvnx-eFrfL2AjgIU5sYnLMDMes5AKpQpIGZALc6FJISDGxotCFJbQ55EIaLgssCbQGU0nAGbvc7W5c99WTD2pde0NNo1vqeq8QQMosT2FEr3aocZ33jqzauHqt3VYBV6MvNfhSv74G9mI_25drqv7JP0H4A1E7ZFM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3116678511</pqid></control><display><type>article</type><title>Patient-reported data on the severity of Von Willebrand disease</title><source>Wiley-Blackwell Full Collection</source><creator>van Kwawegen, Calvin B ; Fijnvandraat, Karin ; Kruip, Marieke J H A ; de Meris, Joke ; Schols, Saskia E M ; Meijer, Karina ; van der Bom, Johanna G ; Cnossen, Marjon H ; van Galen, Karin P M ; Atiq, Ferdows ; Eikenboom, Jeroen ; Leebeek, Frank W G</creator><creatorcontrib>van Kwawegen, Calvin B ; Fijnvandraat, Karin ; Kruip, Marieke J H A ; de Meris, Joke ; Schols, Saskia E M ; Meijer, Karina ; van der Bom, Johanna G ; Cnossen, Marjon H ; van Galen, Karin P M ; Atiq, Ferdows ; Eikenboom, Jeroen ; Leebeek, Frank W G ; WiN study group ; the WiN study group</creatorcontrib><description>The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD.
The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients.
Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL).
We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient-reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72-9.45), higher BS (OR = 1.09, 95%CI: 1.06-1.11), female sex (OR = 1.36, 95%CI: 1.01-1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10-2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07-1.00) were independent determinants of patient-reported severity.
This study shows that patient-reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.</description><identifier>ISSN: 1351-8216</identifier><identifier>ISSN: 1365-2516</identifier><identifier>EISSN: 1365-2516</identifier><identifier>DOI: 10.1111/hae.15103</identifier><identifier>PMID: 39403864</identifier><language>eng</language><publisher>England</publisher><ispartof>Haemophilia : the official journal of the World Federation of Hemophilia, 2024-10</ispartof><rights>2024 The Author(s). Haemophilia published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c210t-4f4c837c037b023ed3e6c16410cab261534f29a9fe3f81826c0693be1aa1cd613</cites><orcidid>0000-0001-5677-1371 ; 0000-0002-0265-4871 ; 0000-0002-3822-1496 ; 0000-0002-3769-9148 ; 0000-0003-3251-8595</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39403864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Kwawegen, Calvin B</creatorcontrib><creatorcontrib>Fijnvandraat, Karin</creatorcontrib><creatorcontrib>Kruip, Marieke J H A</creatorcontrib><creatorcontrib>de Meris, Joke</creatorcontrib><creatorcontrib>Schols, Saskia E M</creatorcontrib><creatorcontrib>Meijer, Karina</creatorcontrib><creatorcontrib>van der Bom, Johanna G</creatorcontrib><creatorcontrib>Cnossen, Marjon H</creatorcontrib><creatorcontrib>van Galen, Karin P M</creatorcontrib><creatorcontrib>Atiq, Ferdows</creatorcontrib><creatorcontrib>Eikenboom, Jeroen</creatorcontrib><creatorcontrib>Leebeek, Frank W G</creatorcontrib><creatorcontrib>WiN study group</creatorcontrib><creatorcontrib>the WiN study group</creatorcontrib><title>Patient-reported data on the severity of Von Willebrand disease</title><title>Haemophilia : the official journal of the World Federation of Hemophilia</title><addtitle>Haemophilia</addtitle><description>The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD.
The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients.
Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL).
We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient-reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72-9.45), higher BS (OR = 1.09, 95%CI: 1.06-1.11), female sex (OR = 1.36, 95%CI: 1.01-1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10-2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07-1.00) were independent determinants of patient-reported severity.
This study shows that patient-reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.</description><issn>1351-8216</issn><issn>1365-2516</issn><issn>1365-2516</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EoqWw4AdQlrBI8XgSJ1khVPGSKsGCx9JynLEalCbFdpD69yS0cDdzNTq6i8PYOfA5DLleaZpDChwP2BRQprFIQR6OPYU4FyAn7MT7T84BBZfHbIJFwjGXyZTdvOhQUxtiR5vOBaqiSgcddW0UVhR5-iZXh23U2eh9-H3UTUOl0-2A1Z60p1N2ZHXj6Wx_Z-zt_u518Rgvnx-eFrfL2AjgIU5sYnLMDMes5AKpQpIGZALc6FJISDGxotCFJbQ55EIaLgssCbQGU0nAGbvc7W5c99WTD2pde0NNo1vqeq8QQMosT2FEr3aocZ33jqzauHqt3VYBV6MvNfhSv74G9mI_25drqv7JP0H4A1E7ZFM</recordid><startdate>20241015</startdate><enddate>20241015</enddate><creator>van Kwawegen, Calvin B</creator><creator>Fijnvandraat, Karin</creator><creator>Kruip, Marieke J H A</creator><creator>de Meris, Joke</creator><creator>Schols, Saskia E M</creator><creator>Meijer, Karina</creator><creator>van der Bom, Johanna G</creator><creator>Cnossen, Marjon H</creator><creator>van Galen, Karin P M</creator><creator>Atiq, Ferdows</creator><creator>Eikenboom, Jeroen</creator><creator>Leebeek, Frank W G</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5677-1371</orcidid><orcidid>https://orcid.org/0000-0002-0265-4871</orcidid><orcidid>https://orcid.org/0000-0002-3822-1496</orcidid><orcidid>https://orcid.org/0000-0002-3769-9148</orcidid><orcidid>https://orcid.org/0000-0003-3251-8595</orcidid></search><sort><creationdate>20241015</creationdate><title>Patient-reported data on the severity of Von Willebrand disease</title><author>van Kwawegen, Calvin B ; Fijnvandraat, Karin ; Kruip, Marieke J H A ; de Meris, Joke ; Schols, Saskia E M ; Meijer, Karina ; van der Bom, Johanna G ; Cnossen, Marjon H ; van Galen, Karin P M ; Atiq, Ferdows ; Eikenboom, Jeroen ; Leebeek, Frank W G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c210t-4f4c837c037b023ed3e6c16410cab261534f29a9fe3f81826c0693be1aa1cd613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Kwawegen, Calvin B</creatorcontrib><creatorcontrib>Fijnvandraat, Karin</creatorcontrib><creatorcontrib>Kruip, Marieke J H A</creatorcontrib><creatorcontrib>de Meris, Joke</creatorcontrib><creatorcontrib>Schols, Saskia E M</creatorcontrib><creatorcontrib>Meijer, Karina</creatorcontrib><creatorcontrib>van der Bom, Johanna G</creatorcontrib><creatorcontrib>Cnossen, Marjon H</creatorcontrib><creatorcontrib>van Galen, Karin P M</creatorcontrib><creatorcontrib>Atiq, Ferdows</creatorcontrib><creatorcontrib>Eikenboom, Jeroen</creatorcontrib><creatorcontrib>Leebeek, Frank W G</creatorcontrib><creatorcontrib>WiN study group</creatorcontrib><creatorcontrib>the WiN study group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Kwawegen, Calvin B</au><au>Fijnvandraat, Karin</au><au>Kruip, Marieke J H A</au><au>de Meris, Joke</au><au>Schols, Saskia E M</au><au>Meijer, Karina</au><au>van der Bom, Johanna G</au><au>Cnossen, Marjon H</au><au>van Galen, Karin P M</au><au>Atiq, Ferdows</au><au>Eikenboom, Jeroen</au><au>Leebeek, Frank W G</au><aucorp>WiN study group</aucorp><aucorp>the WiN study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient-reported data on the severity of Von Willebrand disease</atitle><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle><addtitle>Haemophilia</addtitle><date>2024-10-15</date><risdate>2024</risdate><issn>1351-8216</issn><issn>1365-2516</issn><eissn>1365-2516</eissn><abstract>The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD.
The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients.
Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL).
We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient-reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72-9.45), higher BS (OR = 1.09, 95%CI: 1.06-1.11), female sex (OR = 1.36, 95%CI: 1.01-1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10-2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07-1.00) were independent determinants of patient-reported severity.
This study shows that patient-reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.</abstract><cop>England</cop><pmid>39403864</pmid><doi>10.1111/hae.15103</doi><orcidid>https://orcid.org/0000-0001-5677-1371</orcidid><orcidid>https://orcid.org/0000-0002-0265-4871</orcidid><orcidid>https://orcid.org/0000-0002-3822-1496</orcidid><orcidid>https://orcid.org/0000-0002-3769-9148</orcidid><orcidid>https://orcid.org/0000-0003-3251-8595</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-8216 |
| ispartof | Haemophilia : the official journal of the World Federation of Hemophilia, 2024-10 |
| issn | 1351-8216 1365-2516 1365-2516 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3116678511 |
| source | Wiley-Blackwell Full Collection |
| title | Patient-reported data on the severity of Von Willebrand disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A06%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient-reported%20data%20on%20the%20severity%20of%20Von%20Willebrand%20disease&rft.jtitle=Haemophilia%20:%20the%20official%20journal%20of%20the%20World%20Federation%20of%20Hemophilia&rft.au=van%20Kwawegen,%20Calvin%20B&rft.aucorp=WiN%20study%20group&rft.date=2024-10-15&rft.issn=1351-8216&rft.eissn=1365-2516&rft_id=info:doi/10.1111/hae.15103&rft_dat=%3Cproquest_cross%3E3116678511%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3116678511&rft_id=info:pmid/39403864&rfr_iscdi=true |